.png)
For a century, production models in biopharmaceutical manufacturing have been built around capital and automation. Jason Beckwith, Vice President of Talent Science & Thought Leadership at BioTalent, has published new work extending that model.
Jason's latest publication, From Process Engineering to Workforce Engineering: A Three-Factor Production Model and Simulation Study for Automated Biopharmaceutical Manufacturing, introduces workforce engineering as a proposed new production discipline, one that treats workforce capability as a measurable production asset, standing alongside capital and automation.
A three-factor production model
The publication extends the established biopharmaceutical production function by separating workforce capability from automation capability for the first time — producing a three-factor model in which capital, automation and workforce are each treated as independent, measurable drivers of performance. The paper includes a simulation study of automated biopharmaceutical manufacturing.
Why this matters
Separating workforce capability from automation capability gives organisations a way to think about workforce decisions with the same rigour typically applied to capital or automation investment, relevant for any business scaling, restructuring or planning for its next growth stage.
Read the full paper
Whether you're planning for a new growth stage, assessing organisational readiness, or rethinking how workforce capability is measured within your business, this publication sets out a new way to model that question.